Status:

COMPLETED

Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)

Lead Sponsor:

Gyeongsang National University Hospital

Conditions:

Non-small Cell Lung Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The rationale of phase II study of biweekly docetaxel and cisplatin in patients with unresectable NSCLC are follows: First, the optimal dose and schedule of combination with docetaxel and cisplatin a...

Detailed Description

Study design is followings: The sample size was calculated according to Simon's two stage optimal design. Assuming a response rate of 40%, a probability of error of 5% and a power of 80%, a total of 4...

Eligibility Criteria

Inclusion

  • patients who were≥ 65 years of age and they had an Easten Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, or the patients who were \< 65 years of age and they had an ECOG PS 2
  • histologically confirmed non-small cell carcinoma
  • stages IIIB-IV disease
  • adequate hematologic parameters (hemoglobin concentration of at least 9.0 g/dL, absolute neutrophil count ≥1,500/mm3, and platelet count ≥100,000/mm3), renal function (serum creatinine ≤1.5 mg/dL), and liver function (total bilirubin ≤1.5 mg/dL and serum transaminase level less than twice the upper limit of normal)
  • at least one bi-dimensionally measurable lesion, according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1

Exclusion

  • Active infection
  • Prior chemotherapy, radiotherapy or surgery for their disease,
  • A history of myocardial infarction in the last 3 months before entry to the study
  • Uncontrolled congestive heart failure or hypertension
  • Uncontrolled diabetes mellitus, pregnancy, lactation or a prior second primary cancer except for cervix cancer in situ or skin cancer
  • All the patients provided written informed consent before they entered the study

Key Trial Info

Start Date :

October 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2012

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT00995761

Start Date

October 1 2009

End Date

August 1 2012

Last Update

March 3 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gyeongsang National University Hospital

Jinju, Gyeongsang-Nam-Do, South Korea, 660-702